Shashikant Lele, MD, FACOG Shashikant Lele, MD, FACOG

Shashikant Lele

MD, FACOG
Gynecologic Oncology

Specializing In:

Cervical cancer Endometrial cancer Ovarian cancer Uterine fibroid tumors Vaginal cancer Vulvar cancer

Special Interests:

Gynecologic oncology group studies involving clinical and scientific research Ovarian cancer surgery Ovarian cancer chemotherapy

About Shashikant Lele

Positions

Roswell Park Comprehensive Cancer Center

  • Clinical Chief of Gynecologic Oncology
  • Clinical Chair, Division of Surgical Subspecialties

Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo

  • Clinical Professor of Gynecology & Obstetrics

Background

Education and Training:

  • MD - Grant Medical College, University of Mumbai, Mumbai, Maharashtra, India

Residency:

  • JJ Hospital-Grant Medical College, Mumbai, Maharashtra, India
  • Mount Sinai Hospital, Cleveland, OH

Fellowship:

  • Roswell Park Cancer Institute, Buffalo, NY

Board Certification:

  • Obstetrics & Gynecology, American Board of Obstetrics & Gynecology
  • Gynecologic Oncology, American Board of Obstetrics & Gynecology
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
Learn More
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Learn More
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
Learn More

Clinical Trials

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
Learn More
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Learn More
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
Learn More
Women: Listen to Your Body

Featured on Cancer Talk

Women: Listen to Your Body

Publications

Full Publications list on PubMed
  • Mhawech-Fauceglia P, Wang D, Lele S, Frederick PJ, Pejovic T, Liu S. Claudin7 and moesin in endometrial Adenocarcinoma; a retrospective study of 265 patients. BMC research notes 2012; 5 :65
  • Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, Lele S, DuPont N, Edwards R, Shrikant P, Old LJ, Gnjatic S, Jager E. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proceedings of the National Academy of Sciences of the United States of America 2012; 10915:5797-5802
  • Beck TL, Singhal PK, Ehrenberg HM, Rose PG, Lele SB, Krivak TC, McBee WC. Endometrial stromal sarcoma: analysis of recurrence following adjuvant treatment. Gynecologic oncology 2012; 1251:141-144
  • Shen J, Wang D, Gregory SR, Medico L, Hu Q, Yan L, Odunsi K, Lele SB, Ambrosone CB, Liu S, Zhao H.Evaluation of microRNA expression profiles and their associations with risk alleles in lymphoblastoid cell lines of familial ovarian cancer. Carcinogenesis 2012; 333:604-612
  • Mhawech-Fauceglia P, Wang D, Samrao D, Godoy H, Ough F, Liu S, Pejovic T, Lele S. Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma. Gynecologic oncology 2012; 1271:198-201
  • Mhawech-Fauceglia P, Wang D, Samrao D, Godoy H, Pejovic T, Liu S, Lele S. Pair-Box (PAX8) protein-positive expression is associated with poor disease outcome in women with endometrial cancer.British journal of cancer 2012; 1072:370-374
  • Mhawech-Fauceglia P, Wang D, Samrao D, Menesses T, Godoy H, Ough F, Lele S, Liu S, Pejovic T. The role of hypoxic-inducible factor (HIF1α) and aldolaseC protein in endometrial carcinogenesis: a retrospective study of 279 patients. BMJ open 2012; 24:e001450
  • Dewdney SB, Kizer NT, Andaya AA, Babb SA, Luo J, Mutch DG, Schmidt AP, Brinton LA, Broaddus RR, Ramirez NC, Huettner PC, McMeekin DS, Darcy K, Ali S, Judson PL, Mannel RS, Lele SB, O'Malley DM, Goodfellow PJ. Uterine serous carcinoma: increased familial risk for lynch-associated malignancies.Cancer prevention research (Philadelphia, Pa.) 2012; 53:435-443
  • Agnani D, Camacho-Vanegas O, Camacho C, Lele S, Odunsi K, Cohen S, Dottino P, Martignetti JA.Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression. Journal of ovarian research 2011; 4:18
  • Morgan Jr RJ, Johnston C, Lele S, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Havrilesky LJ, Hakam A, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen L-M, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Werner TL. Epithelial ovarian cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2011; 91:82-113
  • Mhawech-Fauceglia P, Kesterson J, Wang D, Akers S, Dupont NC, Clark K, Lele S, Liu S. Expression and clinical significance of the transforming growth factor-beta signalling pathway in endometrial cancer.Histopathology 2011; 591:63-72
  • Godoy H, Mhawech-Fauceglia P, Beck A, Miller A, Lele S, Odunsi K. Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome. International journal of gynecological pathology 2011; 302:139-144
  • Syriac S, Durie N, Kesterson J, Lele S, Mhawech-Fauceglia P. Female adnexal tumor of probable Wolffian origin (FATWO) with recurrence 3 years postsurgery. International journal of gynecological pathology2011; 303:231-235
  • Mhawech-Fauceglia P, Wang D, Kesterson J, Syriac S, Clark K, Frederick PJ, Lele S, Liu S. Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma. PloS one 2011; 63:e18066
  • Gruber TJ, Fabiano AJ, Deeb G, Lele SB, Fenstermaker RA. Intracranial meningiomas in patients with uterine sarcoma treated with long-term megestrol acetate therapy. World neurosurgery 2011;765:477.e16-477.e20
  • Kanis M, Kesterson JP, Shroff S, Lele S, Mhawech-Fauceglia P. Malignant mixed mullerian tumor of primary peritoneal origin. Annals of diagnostic pathology 2011; 154:273-277
  • , McCloskey SA, Tchabo NE, Malhotra HK, Odunsi K, Rodabaugh K, Singhal P, Lele S, Jaggernauth W.Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation. Gynecologic oncology 2010; 1163:404-407
  • Kesterson JP, Odunsi K, Lele S. High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies. Chemotherapy 2010;562:108-111
  • Mhawech-Fauceglia P, Herrmann FR, Rai H, Tchabo N, Lele S, Izevbaye I, Odunsi K, Cheney RT. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. American journal of clinical pathology 2010; 1336:899-908
  • DuPont NC, Guru KA, Iskander GB, Odunsi K, Lele SB, Rodabaugh KJ. Instituting a robot-assisted surgery programme at a tertiary care cancer centre. International journal of medical robotics and computer assisted surgery 2010; 63:330-333
  • Mhawech-Fauceglia P , Wang D , Kesterson J , Clark K , Monhollen L , Odunsi K , Lele S , Liu S. Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma. PloS one 2010; 511:e15415
  • Shen J, DiCioccio R, Odunsi K, Lele SB, Zhao H. Novel genetic variants in miR-191 gene and familial ovarian cancer. BMC cancer 2010; 10 :47
  • Ali L, Bambach BJ, Kozielski R, Wagner H, Lele S, Mhawech-Fauceglia P. Ovarian yolk sac tumor associated with major fibrosarcoma component in a 13-year-old girl. International journal of gynecological pathology 2010; 293:252-255
  • Paczos TA, Ackers S, Odunsi K, Lele S, Mhawech-Fauceglia P. Primary vaginal adenocarcinoma arising in vaginal adenosis after CO2 laser vaporization and 5-fluorouracil therapy. International journal of gynecological pathology 2010; 292:193-196
  • Mhawech-Fauceglia P , Herrmann RF , Kesterson J , Izevbaye I , Lele S , Odunsi K. Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium.European journal of surgical oncology 2010; 3612:1195-1201
  • Godoy H, Kesterson JP, Lele S. Tumor lysis syndrome associated with carboplatin and paclitaxel in a woman with recurrent endometrial cancer. International journal of gynaecology and obstetrics 2010;1093:254
  • Matsuzaki J, Old LJ, Shrikant P, Lele S, Qian F, Eppolito C, Tsuji T, Miller A, Beck A, Mhawech-Fauceglia P, Gnjatic S, Odunsi K. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 2010; 10717:7875-7880
  • Mhawech-Fauceglia P, Herrmann FR, Andrews C, South S, Beck A, Lele S, Odunsi K. 14-3-3sigma Expression and Prognostic Value in Patients with Epithelial Ovarian Carcinoma: a High Throughput Tissue Microarray Analysis. European journal of surgical oncology 2009; 357:763-767
  • Tayo BO, DiCioccio RA, Liang Y, Trevisan M, Cooper RS, Lele S, Sucheston L, Piver SM, Odunsi K.Complex segregation analysis of pedigrees from the Gilda Radner Familial Ovarian Cancer Registry reveals evidence for mendelian dominant inheritance. PloS one 2009; 46:e5939
  • Lin B, White JT, Wu J, Lele S, Old LJ, Hood L, Odunsi K. Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer. Proteomics. Clinical applications 2009; 37:853-861
  • Qian F, Old LJ, Shrikant P, Lele S, Moysich K, Cheney R, Liao J, Beck A, Frederick PJ, Ayyoub M, Valmori D, Matsuzaki J, Andrews C, Tario Jr JD, Mhawech-Fauceglia P, Wallace PK, Villella J, Odunsi K. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer research 2009;6913:5498-5504
  • Tchabo NE, Old LJ, Lele S, Andrews C, Liao J, Miliotto AJ, Beck AF, Villella J, Caballero OL, Mhawech-Fauceglia P, Odunsi K. Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. Cancer immunity 2009; 9:6
  • Mhawech-Fauceglia P, Herrmann FR, Wagner H, Godoy H, Odunsi K, Cheney RT, Lele S. Submission of the entire lymph node dissection for histologic examination in gynecologic-oncologic specimens. Clinical and pathologic relevance. Gynecologic oncology 2009; 1153:354-356
  • Kanis M, Kesterson JP, Lele S. The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia. European journal of gynaecological oncology 2009; 304:387-388
  • Tchabo NE, McCloskey S, Mashtare TL, Andrews C, Singh AK, Mhawech-Fauceglia P, Odunsi K, Lele S, Jaggernauth W. Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006. Gynecologic oncology 2009; 1152:249-256
  • Kesterson JP, Lele S. Vulvar intraepithelial neoplasia 3 in women less than 35 years. Journal of lower genital tract disease 2009; 134:196-199
  • Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB, Zhao H. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis 2008; 2910:1963-1966
  • Smith R, Hicks D, Tomljanovich PI, Lele SB, Rajput A, Dunn KB. Adenocarcinoma arising from chronic perianal Crohn's disease: case report and review of the literature. American surgeon 2008; 741:59-61
  • Mhawech-Fauceglia P, Pejovic T, Dim D, Fang X, Conroy J, Lele S, Cheney R, Odunsi K. Array-based comparative genomic hybridization (aCGH) analysis is a useful tool for distinguishing primary pulmonary from metastatic neuroendocrine carcinoma to the lung. Applied immunohistochemistry and molecular morphology : AIMM 2008; 163:291-295
  • Mhawech-Fauceglia P, Odunsi K, Dim D, Nowak N, Lele S, Cheney RT, Pejovic T. Array-comparative genomic hybridization analysis of primary endometrial and ovarian high-grade neuroendocrine carcinoma associated with adenocarcinoma: mystery resolved? . International journal of gynecological pathology 2008; 274:539-546
  • Partridge EE, Wilczynski S, Valea F, Trimble CL, Teng N, Smith-McCune K, Singh DK, Reynolds RK, Nava ME, Morgan M, Lipscomb GH, Lieberman RW, Lele SM, Greer BE, Fahey PJ, Campos S, Abu-Rustum N, National Comprehensive Cancer Network. Cervical cancer screening. Journal of the National Comprehensive Cancer Network : JNCCN 2008; 61:58-82
  • Tosello V, Odunsi K, Souleimanian NE, Lele S, Shrikant P, Old LJ, Valmori D, Ayyoub M. Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs. Clinical immunology (Orlando, Fla.) 2008; 1263:291-302
  • Mhawech-Fauceglia P, Herrmann F, Bshara W, Zhang S, Penetrante R, Lele S, Odunsi K, Rodabaugh K.Intraobserver and interobserver variability in distinguishing between endocervical and endometrial adenocarcinoma on problematic cases of cervical curettings. International journal of gynecological pathology 2008; 273:431-436
  • Tchabo NE, Mhawech-Fauceglia P, Lele S. Primary squamous cell carcinoma of the endometrium: a case report. European journal of gynaecological oncology 2008; 295:527-530
  • Mhawech-Fauceglia P, Herrmann F, Lele S, Higgs D, South S, Schwaller J, Andrews C, Bshara W, Smiraglia DJ, Odunsi K. Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinoma. Cancer epidemiology, biomarkers and prevention 2008;173:571-577
  • Matsuzaki J, Qian F, Luescher I, Lele S, Ritter G, Shrikant PA, Gnjatic S, Old LJ, Odunsi K. Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. Cancer immunology, immunotherapy : CII 2008; 578:1185-1195
  • Kesterson JP, South S, Lele S. Squamous cell carcinoma of the vulva in a young woman with Crohn's disease. European journal of gynaecological oncology 2008; 296:651-652
  • Kesterson JP, Mhawech-Fauceglia P, Lele S. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecologic oncology 2008; 1113:527-529
  • Sharma S, Tammela J, Wang X, Arnouk H, Driscoll D, Mhawech-Fauceglia P, Lele S, Kazim AL, Odunsi K.Characterization of a putative ovarian oncogene, elongation factor 1alpha, isolated by panning a synthetic phage display single-chain variable fragment library with cultured human ovarian cancer cells. Clinical cancer research 2007; 1319:5889-5896
  • Villella J, Herrmann FR, Kaul S, Lele S, Marchetti D, Natiella J, Odunsi K, Mhawech-Fauceglia P. Clinical and pathological predictive factors in women with adult-type granulosa cell tumor of the ovary.International journal of gynecological pathology 2007; 262:154-159
  • Rodabaugh KJ, Mhawech-Fauceglia P, Groth J, Lele S, Sood AK. Prostate-derived Ets factor is overexpressed in serous epithelial ovarian tumors. International journal of gynecological pathology2007; 261:10-15
  • Odunsi K, Old LJ, Shrikant P, Lele S, Rodabaugh K, Thomas B, Villella J, Ritter G, Pan L, Hoffman EW, Andrews C, Mhawech-Fauceglia P, Matsuzaki J, Qian F, Gnjatic S. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.Proceedings of the National Academy of Sciences of the United States of America 2007; 10431:12837-12842
  • Shamshirsaz AA, Withiam-Leitch M, Odunsi K, Baker T, Frederick PJ, Lele S. Young patients with endometrial carcinoma selected for conservative treatment: a need for vigilance for synchronous ovarian carcinomas, case report and literature review. Gynecologic oncology 2007; 1043:757-760